EGFR and lung cancer: Despite the high response rates (52.7%–83%) of TKIs used in treating patients with stage IIIb or IV lung cancer with active EGFR mutations, such patients eventually succumb to this disease; To further improve the outcome, more aggressive treatment might be necessary for some patients.